Skip to content
sellModerate cluster of 7

Georges Gemayel sold $1.0M of SUPN

director at SUPERNUS PHARMACEUTICALS, INC.. 18,787 shares at an average of $53.38, traded Mar 5, 2026, filed Mar 9, 2026.

Warning score
50
Value
$1.0M
18,787 shares
Holdings after
27,277
-49% from before
From 52-week low
+79%
low $30.29, close $54.27
From 52-week high
-5%
high $57.00, as of Mar 5, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $1.0M at market
    +25
  • Share of holdings sold
    Sold 49% of holdings
    +10
  • Cluster
    7 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -4.7%, 3m -17.9%, 6m -19.6%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

SUPNOct 9, 2026 · close 42.67
Since filing Mar 9, 2026: -21.2%SPY +15.6% · excess -36.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001256088-26-000006, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 5, 2026SOpen-market sale
Common Stock
-10,000$53.71$537k28,159Mar 9, 2026
Mar 6, 2026MOption exercise
Common Stock
+7,905$25.30$200k36,064Mar 9, 2026
Mar 6, 2026SOpen-market sale
Common Stock
-8,787$53.00$466k27,277Mar 9, 2026
Mar 6, 2026MOption exercise
Director Stock Option (Right to Buy)derivative
-7,905$0.00$00Mar 9, 2026

Related signals

Other insiders at SUPERNUS PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
40Moderate
SUPNsell 610b5-1
SUPERNUS PHARMACEUTICALS, INC.
Padmanabh P. Bhatt
Sr. VP of IP, CSO
$5.4M
107,250 shares
-160%
43Moderate
SUPNsell 6
SUPERNUS PHARMACEUTICALS, INC.
Frederick M. Hudson
director
$272k
5,369 shares
-8%
45Moderate
SUPNsell 610b5-1
SUPERNUS PHARMACEUTICALS, INC.
Jack A. Khattar
President, CEO
$1.8M
35,000 shares
-4%
53Moderate
SUPNsell 6
SUPERNUS PHARMACEUTICALS, INC.
William Todd Horich
SVP, Commercial Operations
$484k
8,877 shares
-100%
24Weak
SUPNsell 6
SUPERNUS PHARMACEUTICALS, INC.
Frank Mottola
SVP, Chief Tech. Ops. Officer
$87k
1,623 shares
-8%
21Weak
SUPNsell 210b5-1
SUPERNUS PHARMACEUTICALS, INC.
Bethany Sensenig
director
$228k
4,475 shares
-100%
33Weak
SUPNsell 210b5-1
SUPERNUS PHARMACEUTICALS, INC.
Frank Mottola
SVP, Chief Tech. Ops. Officer
$1.0M
20,000 shares
-98%
13Weak
SUPNsell 2
SUPERNUS PHARMACEUTICALS, INC.
Padmanabh P. Bhatt
Sr. VP of IP, CSO
$32k
710 shares
-5%
23Weak
SUPNsell 210b5-1
SUPERNUS PHARMACEUTICALS, INC.
Jack A. Khattar
President, CEO
$3.0M
59,900 shares
-5%
33Weak
SUPNsell 210b5-1
SUPERNUS PHARMACEUTICALS, INC.
Charles W Newhall III
director
$1.3M
25,000 shares
-19%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Georges Gemayel sold $1.0M of SUPN | InsiderTell